MX2018013008A - Anticuerpos st-2 humanos solubles y ensayos. - Google Patents

Anticuerpos st-2 humanos solubles y ensayos.

Info

Publication number
MX2018013008A
MX2018013008A MX2018013008A MX2018013008A MX2018013008A MX 2018013008 A MX2018013008 A MX 2018013008A MX 2018013008 A MX2018013008 A MX 2018013008A MX 2018013008 A MX2018013008 A MX 2018013008A MX 2018013008 A MX2018013008 A MX 2018013008A
Authority
MX
Mexico
Prior art keywords
antibodies
assays
soluble human
antibody fragments
antigen
Prior art date
Application number
MX2018013008A
Other languages
English (en)
Inventor
James V Snider
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of MX2018013008A publication Critical patent/MX2018013008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)

Abstract

La presente invención se refiere a un método in vitro para seleccionar un tratamiento terapéutico par aun sujeto en necesidad del mismo, el método que comprende: determinar un nivel del gen 2 expresado por estimulación de crecimiento (ST2) soluble, humano, en una muestra que comprende sangre, suero o plasma de un sujeto utilizando un anticuerpo aislado producido por el hibridoma depositado en la Biblioteca Amerciana de Cultivos Tipo (ATCC) y designado por la Designación de Depósito de Patente PTA-10432, o un fragmento de unión al antígeno de un anticuerpo producido por el hibrido depositado en la ATCC y designado por la Designación de depósito de Patente PTA-10432; e identificar un sujeto que tiene un nivel elevado de ST2 soluble humano en la muestra comparado con un nivel de referencia de ST2 soluble humano como el sujeto que necesita el tratamiento terapéutico y seleccionar un tratamiento terpéutico para el sujeto, en donde el tratamiento terapéutico para el sujeto, en donde el tratamiento terapéutico se selecciona del grupo que consiste de un nitrato, un bloqueador de canales de calcio, un diurético, un agente trombolítico, digitalis, un agente modular del sistema de renina-angiotensina-aldosterona (RAAS), un inhibidor de la enzima convertidora de angiotensina, un antagonista de aldosterona, un inhibidor de renina, un bloqueador del.
MX2018013008A 2010-04-09 2011-04-08 Anticuerpos st-2 humanos solubles y ensayos. MX2018013008A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32257810P 2010-04-09 2010-04-09
US34583710P 2010-05-18 2010-05-18
PCT/US2011/031801 WO2011127412A2 (en) 2010-04-09 2011-04-08 Soluble human st-2 antibodies and assays

Publications (1)

Publication Number Publication Date
MX2018013008A true MX2018013008A (es) 2022-02-15

Family

ID=44763578

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018013008A MX2018013008A (es) 2010-04-09 2011-04-08 Anticuerpos st-2 humanos solubles y ensayos.
MX2014007960A MX360543B (es) 2010-04-09 2011-04-08 Anticuerpos st-2 humanos solubles y ensayos.
MX2012011667A MX2012011667A (es) 2010-04-09 2011-04-08 Anticuerpos st-2 humanos solubles y ensayos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2014007960A MX360543B (es) 2010-04-09 2011-04-08 Anticuerpos st-2 humanos solubles y ensayos.
MX2012011667A MX2012011667A (es) 2010-04-09 2011-04-08 Anticuerpos st-2 humanos solubles y ensayos.

Country Status (19)

Country Link
US (4) US8420785B2 (es)
EP (4) EP2556090B1 (es)
JP (5) JP5635180B2 (es)
CN (2) CN103154027B (es)
AU (1) AU2011237359B2 (es)
BR (1) BR112012025728B1 (es)
CA (1) CA2795200C (es)
DK (1) DK2556090T3 (es)
ES (3) ES2859577T3 (es)
HR (1) HRP20160461T1 (es)
HU (1) HUE027760T2 (es)
IL (2) IL222276B (es)
MX (3) MX2018013008A (es)
PL (1) PL2556090T3 (es)
RS (1) RS54762B1 (es)
RU (3) RU2625014C2 (es)
SG (2) SG184450A1 (es)
SI (1) SI2556090T1 (es)
WO (1) WO2011127412A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
US20090305265A1 (en) * 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
CA2650963C (en) 2006-05-01 2020-09-15 Critical Care Diagnostics, Inc. St2 as a cardiovascular disease marker for high-bmi or impaired renal function patients
DK2019965T3 (en) * 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
EP3093663B1 (en) 2008-04-18 2018-06-13 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
SI2556090T1 (sl) 2010-04-09 2016-07-29 Critical Care Diagnostics, Inc. Protitelesa in testi topnega človeškega ST-2
GB201013151D0 (en) * 2010-08-04 2010-09-22 Isis Innovation Diagnostic method
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
EP3173093B1 (en) 2011-07-18 2018-12-05 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
JO3623B1 (ar) * 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
US20130345805A1 (en) 2012-05-18 2013-12-26 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
CN102830234A (zh) * 2012-08-10 2012-12-19 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
CN105785028A (zh) * 2012-08-10 2016-07-20 杭州华得森生物技术有限公司 一种检测人心力衰竭新型标志物st2的快速诊断试剂盒
CN104737023B (zh) 2012-08-16 2017-07-28 重症监护诊断股份有限公司 预测患高血压风险的方法
AU2013305829A1 (en) * 2012-08-21 2015-03-05 Critical Care Diagnostics, Inc. Multimarker risk stratification
WO2015106081A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
CN103926406A (zh) * 2014-04-29 2014-07-16 安徽省立医院 一种指示肝炎感染的标志物及其用途
US10324089B2 (en) * 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
AU2015360396A1 (en) * 2014-12-11 2017-06-29 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
CN105259353B (zh) * 2015-10-15 2017-03-22 北京市心肺血管疾病研究所 一种主动脉瘤和/或主动脉夹层患者血液中可溶性st2的检测试剂盒及检测方法
CN107765014B (zh) * 2016-08-23 2019-11-19 上海费玛生物科技有限公司 一种检测人sST2蛋白的方法以及试剂盒
CN108956996A (zh) * 2017-05-23 2018-12-07 深圳市安群生物工程有限公司 检测人st2蛋白的荧光免疫层析试纸及其制备方法
CN107340386A (zh) * 2017-06-09 2017-11-10 厦门大学附属中山医院 基于微粒子化学发光免疫分析的sST2检测试剂盒
CN108152486A (zh) * 2017-12-22 2018-06-12 太原瑞盛生物科技有限公司 一种人可溶性st2的磁微粒化学发光检测试剂盒及制备方法
US20210403579A1 (en) * 2018-10-31 2021-12-30 Delinia, Inc. Multivalent regulatory t cell modulators
CN110208549A (zh) * 2019-07-01 2019-09-06 北京利德曼生化股份有限公司 一种可溶性生长刺激表达基因2蛋白sST2发光试剂盒
CN110357963B (zh) * 2019-07-31 2020-09-18 北京智仁美博生物科技有限公司 抗人st2抗体及其用途
CN111308086B (zh) * 2020-02-21 2022-02-25 苏州旭光科星抗体生物科技有限公司 一种检测可溶性st2含量的酶联免疫检测试剂盒及用途
CN111863259A (zh) * 2020-08-06 2020-10-30 复旦大学附属中山医院 基于sST2评价肿瘤免疫治疗相关性心肌炎的预后模型及其应用
CN112457392B (zh) * 2021-01-27 2021-04-27 天津奇云诺德生物医学有限公司 一种可溶性st2蛋白抗原决定簇多肽及其应用
CN112924697A (zh) * 2021-01-29 2021-06-08 中翰盛泰生物技术股份有限公司 sST2在CAP患者的预后风险预测中的用途
CN113912729B (zh) * 2021-12-08 2022-03-04 南京融捷康生物科技有限公司 针对sST2的单域抗体及其衍生蛋白和应用
CN114870001A (zh) * 2022-07-07 2022-08-09 北京市心肺血管疾病研究所 Il-33在制备预防和/或治疗主动脉夹层的药物中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE388694B (sv) 1975-01-27 1976-10-11 Kabi Ab Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5073484A (en) 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4743560A (en) 1984-03-26 1988-05-10 Becton Dickinson And Company Solid phase assay
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
JPS61122292A (ja) 1984-11-16 1986-06-10 Teijin Ltd 新規カルバサイクリン中間体の製法
DE3445816C1 (de) 1984-12-15 1986-06-12 Behringwerke Ag, 3550 Marburg Flaechenfoermiges diagnostisches Mittel
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4855240A (en) 1987-05-13 1989-08-08 Becton Dickinson And Company Solid phase assay employing capillary flow
CA1313616C (en) 1987-06-01 1993-02-16 Robert B. Sargeant Lateral flow, non-bibulous membrane protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5229073A (en) 1992-02-27 1993-07-20 Abbott Laboratories One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein(a)
EP0831714A1 (en) 1995-06-07 1998-04-01 Merck & Co., Inc. Monospecific antibodies and methods using them
AU6720096A (en) 1995-08-09 1997-03-05 Quidel Corporation Test strip and method for one step lateral flow assay
AU6277498A (en) 1997-02-15 1998-09-08 Beth Israel Deaconess Medical Center Multiple-site antibody capture immunoassays and kits
DE19711932A1 (de) * 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
GB9727172D0 (en) * 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (fr) * 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
DK3072978T3 (en) * 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
US7435590B2 (en) * 2003-03-14 2008-10-14 Taisho Pharmaceutical Co., Ltd. Monoclonal antibody and hybridoma producing the same
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
SG10201600950TA (en) 2005-11-28 2016-03-30 Genmab As Recombinant monovalent antibodies and methods for production thereof
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
US20090305265A1 (en) 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
CA2650963C (en) * 2006-05-01 2020-09-15 Critical Care Diagnostics, Inc. St2 as a cardiovascular disease marker for high-bmi or impaired renal function patients
DK2019965T3 (en) 2006-05-02 2015-07-20 Critical Care Diagnostics Inc DIFFERENTIAL BETWEEN LUNG AND Cardiovascular Disease
WO2007140205A2 (en) * 2006-05-24 2007-12-06 Biogen Idec Ma Inc. Methods of treating fibrosis
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3093663B1 (en) 2008-04-18 2018-06-13 Critical Care Diagnostics, Inc. Predicting risk of major adverse cardiac events
EP2112149A1 (de) * 2008-04-22 2009-10-28 Bayer CropScience Aktiengesellschaft 2-[(1h-Pyrazol-4-ylmethyl)-sulfonyl]-Oxazol-Derivate, 2-[(1H-Pyrazol-4-ylmethyl)-sulfanyl]-Oxazol-Derivate und chirale 2-[(1H-Pyrazol-4-ylmethyl)-sulfinyl]-Oxazol-Derivate, Verfahren zu deren Herstellung sowie deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
WO2010025393A2 (en) * 2008-08-28 2010-03-04 The Regents Of The University Of California Protein biomarkers and methods for diagnosing kawasaki disease
DE102010044817A1 (de) 2009-09-09 2011-03-10 Burkhard Schmitz Trennwandsystem
SI2556090T1 (sl) * 2010-04-09 2016-07-29 Critical Care Diagnostics, Inc. Protitelesa in testi topnega človeškega ST-2
JP6215713B2 (ja) 2011-03-17 2017-10-18 クリティカル ケア ダイアグノスティクス インコーポレイテッド 有害臨床転帰のリスクを予測する方法
EP3173093B1 (en) 2011-07-18 2018-12-05 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
US20130345805A1 (en) * 2012-05-18 2013-12-26 Cardiac Pacemakers, Inc. Methods for treating or predicting risk of a ventricular tachyarrhythmia event
CN104737023B (zh) 2012-08-16 2017-07-28 重症监护诊断股份有限公司 预测患高血压风险的方法
AU2013305829A1 (en) 2012-08-21 2015-03-05 Critical Care Diagnostics, Inc. Multimarker risk stratification
WO2015106081A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure

Also Published As

Publication number Publication date
RU2625014C2 (ru) 2017-07-11
JP6563976B2 (ja) 2019-08-21
ES2571994T3 (es) 2016-05-27
JP7064034B2 (ja) 2022-05-09
RU2019109844A (ru) 2020-10-05
HRP20160461T1 (hr) 2016-06-17
CN106620692A (zh) 2017-05-10
US20130177931A1 (en) 2013-07-11
CN103154027A (zh) 2013-06-12
US20200339695A1 (en) 2020-10-29
EP3050901A1 (en) 2016-08-03
WO2011127412A3 (en) 2012-01-26
JP2019191199A (ja) 2019-10-31
US10745484B2 (en) 2020-08-18
IL262649B (en) 2021-12-01
SG10201704453YA (en) 2017-07-28
ES2859577T3 (es) 2021-10-04
IL262649A (en) 2018-12-31
CA2795200A1 (en) 2011-10-13
RU2012147638A (ru) 2014-05-27
AU2011237359A1 (en) 2012-11-01
EP3434694B1 (en) 2020-12-30
RU2017121298A (ru) 2019-01-28
RU2684724C2 (ru) 2019-04-11
EP3050901B1 (en) 2018-08-29
ES2699591T3 (es) 2019-02-11
CN106620692B (zh) 2021-04-09
PL2556090T3 (pl) 2017-07-31
JP2015091798A (ja) 2015-05-14
CN103154027B (zh) 2016-06-29
US20110256635A1 (en) 2011-10-20
EP2556090A2 (en) 2013-02-13
AU2011237359B2 (en) 2016-02-04
MX360543B (es) 2018-10-24
US8420785B2 (en) 2013-04-16
DK2556090T3 (en) 2016-05-30
EP3848394A1 (en) 2021-07-14
US9150654B2 (en) 2015-10-06
MX2012011667A (es) 2013-03-05
JP2017173337A (ja) 2017-09-28
HUE027760T2 (en) 2016-11-28
JP2021092587A (ja) 2021-06-17
EP2556090A4 (en) 2013-08-21
JP5635180B2 (ja) 2014-12-03
IL222276A0 (en) 2012-12-31
JP6849751B2 (ja) 2021-03-31
EP2556090B1 (en) 2016-02-24
JP2013523840A (ja) 2013-06-17
BR112012025728B1 (pt) 2022-01-11
IL222276B (en) 2018-11-29
BR112012025728A2 (pt) 2020-09-01
SI2556090T1 (sl) 2016-07-29
RS54762B1 (sr) 2016-10-31
CA2795200C (en) 2020-01-14
US20150361177A1 (en) 2015-12-17
EP3434694A1 (en) 2019-01-30
JP6151676B2 (ja) 2017-06-21
SG184450A1 (en) 2012-11-29
RU2017121298A3 (es) 2019-01-28
WO2011127412A2 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
MX360543B (es) Anticuerpos st-2 humanos solubles y ensayos.
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
NZ607680A (en) Novel antigen binding proteins
PH12014502527B1 (en) St2 antigen binding proteins
PH12014502641B1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
MY162752A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
WO2013188693A8 (en) Antigen binding constructs to cd3
AU2009260320A8 (en) Antibodies to IL-6 and their uses
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
CL2012002662A1 (es) Anticuerpos bivalentes biespecificos anti-veg y un segundo sitio de unión a antígeno que se une específicamente a ang-2 humana; composicion farmacéutica que comprende dicho anticuerpo; método de tratamiento de un paciente que sufre cancer; acido nucleico codificante de dicho anticuerpo, vector de expresión y célula huesped que contiene dicho ácido nucleico.
MX345092B (es) Anticuerpos anti-tau humanos,.
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
EP2579895A4 (en) ANTI-VEGF ANTIBODIES AND USES THEREOF
MX343659B (es) Proteínas de unión receptoras fc.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201000053A1 (ru) Новые антитела
MX347247B (es) Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad.
WO2013122544A3 (en) IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.